Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BBOX1 | O75936 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1111598 | 0.87 | DNM1 (0.35) | BBOX1CYP3A4TSHRTDP1LMNA | |
| SCHEMBL1111576 | 0.87 | BBOX1 (0.31) | BBOX1 | |
| SCHEMBL5011415 | 0.80 | BBOX1 (0.46) | BBOX1CYP3A4TSHRTDP1LMNA | |
| SCHEMBL24072018 | 0.78 | BBOX1 (0.44) | BBOX1CYP3A4TSHRTDP1LMNA | |
| Sulfuric Acid SCHEMBL17102671 | 0.78 | BBOX1 (0.47) | BBOX1CYP3A4TSHRTDP1LMNA | |
| SCHEMBL5009177 | 0.78 | BBOX1 (0.47) | BBOX1CYP3A4TSHRTDP1LMNA | |
| SCHEMBL1111660 | 0.78 | LMNA (0.38) | BBOX1CYP3A4TSHRTDP1LMNA | |
| SCHEMBL1111653 | 0.78 | LMNA (0.38) | BBOX1CYP3A4TSHRTDP1LMNA | |
| SCHEMBL1111634 | 0.78 | BBOX1 (0.44) | BBOX1CYP3A4TSHRTDP1LMNA | |
| Sulfuric Acid SCHEMBL21195064 | 0.77 | BBOX1 (0.46) | BBOX1CYP3A4TSHRTDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2279192-B1 | IONIC LIQUIDS | MERCK PATENT GMBH (DE) | 2013-10-30 | — | — | EP | claimed |
| US-8642778-B2 | Ionic liquids | MERCK PATENT GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| EP-2279192-B1 | IONIC LIQUIDS | MERCK PATENT GMBH (DE) | 2013-10-30 | — | — | EP | disclosed |
| US-20110152537-A1 | IONIC LIQUIDS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-06-23 | — | — | US | disclosed |
| EP-2279192-A2 | IONIC LIQUIDS | Merck Patent GmbH (DE) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009152902-A2 | IONIC LIQUIDS | MERCK PATENT GMBH, (DE) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152537-A1 | IONIC LIQUIDS | HCN3, CHRNA3, CHRM3 | BBOX1 4217/4885CYP3A4 2252/4885TSHR 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.